Clinical Feasibility of ROBERT-SAS in Severely Impaired Stroke Patients

September 15, 2023 updated by: Roessingh Research and Development
Robotic training can be used to provide intensive training during the (early phases of) rehabilitation of a stroke. ROBERT®-SAS training is designed to create an active and intensive training tool for the rehabilitation of the lower extremity of stroke patients. Currently this has only be tested in a lab-based setting, which showed that is was feasible and could be executed while still being comfortable for the patient. The next step will be implementing the device in a clinical setting. Therefore, aims the current study to assess the feasibility of ROBERT®-SAS training in clinical setting, in acute stroke patients.

Study Overview

Status

Completed

Conditions

Detailed Description

Rationale: Stroke is one of the leading causes of disability of adults in the European Union. Around 80% of stroke survivors experience deficits in motor control, resulting in problems with keeping balance and walking, for instance. The extent and amount of deficits differ per individual. Interventions to train the lower extremity almost always consist of walking exercises. However, patients in the acute phase or with severely affected lower extremity function are often unable to walk or to walk independently. Therefore, the combination of a robot (ROBERT®) and functional electrical stimulation (ES) is being developed to provide a training tool for early rehabilitation. In the current study a combination of robot and ES will be evaluated in clinical setting.

Objective: The primary objective of the current study is to assess the feasibility of ROBERT®-SAS training in clinical setting, in acute stroke patients, including patient and therapist perspectives.

Study design: The current study is an observational study.

Study population: In the current study ten (sub) acute stroke patient will be included, with severely affected lower extremity. Five of these ten will be included as soon as possible after arrival at the rehabilitation centre. Another five will be included 3-5 weeks after arrival/start of the rehabilitation.

Main study parameters/endpoints: The main outcome parameter is the SUS score from both the patients and the therapists.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The current study consists of several measurement sessions in Roessingh Rehabilitation Centre, during the normal rehabilitation time. The robot, ROBERT® is CE-certified. However, the combination ROBERT®-SAS, combining both ES and robot support, is not, although previous tests have shown this approach is possible and tolerable by healthy persons and stroke patients. The risks are regarded as minimal because it is without invasive procedures, with room for rest in between trial sets as required by the participant, and application of individual stimulation profiles to not exceed tolerance levels or inflict pain during electrostimulation.

Study Type

Interventional

Enrollment (Actual)

9

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Overijssel
      • Enschede, Overijssel, Netherlands, 7522AH
        • Roessingh Research and Development

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Sub(acute) stroke (< 6 months post-stroke)
  • Above 18 years
  • Able to provide informed consent
  • An ischemic or haemorrhagic stroke
  • Hemiparetic lower extremity

Exclusion Criteria:

  • Premorbid disability of lower extremity
  • Severe cognitive impairment, unable to follow simple instructions and unable to understand Dutch.
  • Skin lesions at the hemiparetic leg
  • Progressive neurological diseases (i.e. Parkinson, dementia, etc.)
  • Contraindication for mobilization like unhealed lower limb fracture
  • Use of pacemaker

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Device Feasibility
  • Allocation: Non-Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Early training group
The early group will receive robotic training combined with electrical stimulation as soon as possible after submission to the rehab center. With a frequency of three times a week for 3-5 weeks, dependent on the capabilities of the patients.
Active training of movements in supine position. Movements such as knee extension and ankle dorsal flexion.
Active Comparator: Late training group
The late training group will receive robotic training combined with electrical stimulation 3-5 weeks after submission to the rehab center. With a frequency of three times a week for 3-5 weeks, dependent on the capabilities of the patients.
Active training of movements in supine position. Movements such as knee extension and ankle dorsal flexion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
System Usability Scale (SUS) score
Time Frame: 15 minutes
The System Usability Scale of patients and therapists. 10 questions with a 5-point response scale. The total score can range from 0 - 100, in which a higher score indicates a better usability
15 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Electromyography (EMG)
Time Frame: 30 minutes
Surface EMG of the muscle that will be stimulated with electrical stimulation, expressed in volt.
30 minutes
Force
Time Frame: 30 minutes
Resulting force measured with the robot, expressed in kg
30 minutes
Frequency
Time Frame: 30 minutes
As a settings of the stimulation expressed in Hertz
30 minutes
Assist-As-Needed (AAN) stages
Time Frame: 30 minutes
The trajectory completion rate for the different stages of AAN. (different types of assistance). There are three different types, no assistance, electrical stimulation assistance and an combination of electrical stimulation and robot support.
30 minutes
Fugl-Meyer Assessment (FMA)
Time Frame: 10 minutes
Lower extremity module, to assess leg function. Scores can range between 0 and 28, in which a higher score indicates a higher leg function.
10 minutes
Motricity Index (MI)
Time Frame: 10 minutes
Lower extremity part, to assess the leg function. Scored for Ankle, knee and hip separately between 0 - 33 in which zero is know movement and 33 is normal movement. Total score can range between 0 - 99. (summation of the three joints)
10 minutes
Functional Ambulation Categories (FAC)
Time Frame: 5 minutes
To assess the walking capabilities, score between 0 and 5, in which 5 indicates a better walking capability.
5 minutes
Type of movement
Time Frame: 30 minutes
Type of movement that will be trained during the measurements. Can be knee extension or ankle dorsal flexion with electrical stimulation.
30 minutes
Questionnaire Experience
Time Frame: 15 minutes
Questions about their experience with ROBERT for all stakeholders. Open questions which will not have a score, but will be interpreted on question level.
15 minutes
Pulse width of the electrical stimulation
Time Frame: 30 minutes
As a settings of the stimulation expressed in milliseconds
30 minutes
Amplitude of the electrical stimulation
Time Frame: 30 Minutes
As a settings of the stimulation expressed in milliampere
30 Minutes
Amount of repetitions
Time Frame: 30 minutes
The amount of repetitions during one set of a specific movement.
30 minutes
Resistance level
Time Frame: 30 minutes
The amount of resistance during the training, can be changed during a set if necessary. The resistance can differ between 0-10, in which 10 is the heaviest.
30 minutes

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gender
Time Frame: 1 minutes
gender will be noted as subject characteristic
1 minutes
Age
Time Frame: 1 minutes
Age will be noted as subject characteristic in years
1 minutes
Time since stroke
Time Frame: 1 minutes
time science stroke will be noted as subject characteristic in months
1 minutes
Weight
Time Frame: 1 minutes
Weight will be noted as subject characteristic and used for BMI calculation, noted in kg
1 minutes
Height
Time Frame: 1 minutes
Height will be noted as subject characteristic and used for BMI calculation, noted in meters
1 minutes
Affected side
Time Frame: 1 minutes
The affected side will be used as subject characteristic
1 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gerdienke Prange, PhD, Roessingh Research and Development

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 11, 2022

Primary Completion (Actual)

August 24, 2023

Study Completion (Actual)

August 24, 2023

Study Registration Dates

First Submitted

June 9, 2022

First Submitted That Met QC Criteria

June 14, 2022

First Posted (Actual)

June 16, 2022

Study Record Updates

Last Update Posted (Actual)

September 18, 2023

Last Update Submitted That Met QC Criteria

September 15, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe